BioLineRx Ltd. (BLRX) Surges on Second Hep-C Play, Traders Raise Eyebrows
Tweet
Share
E-mailGet Alerts BLRX Hot Sheet
Join SI Premium – FREE
Shares of BioLineRx (NASDAQ: BLRX) is surging 31 percent higher early Monday after the company announced it licensed its second oral hepatitis C treatment.
The company signed an exclusive with Genoscience and RFS Pharma for development and commercialization of BL-8030.
A few week ago the stock surged after an exclusive license for BL-8020. Hep-C has been a hot area due to the frenzied M&A in the space.
Investors and traders should keep in mind that after ramping from $3.29 to $6.87 on the first hep-C deal, shares crashed back down to below $4. Some are skeptical of the recent developments.
The company signed an exclusive with Genoscience and RFS Pharma for development and commercialization of BL-8030.
A few week ago the stock surged after an exclusive license for BL-8020. Hep-C has been a hot area due to the frenzied M&A in the space.
Investors and traders should keep in mind that after ramping from $3.29 to $6.87 on the first hep-C deal, shares crashed back down to below $4. Some are skeptical of the recent developments.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Irenic Capital opposes Independence Realty's Centerspace deal - Bloomberg
- Amentum wins $572M contract for Cheyenne Mountain defense systems
- Israel finance ministry recommends against revised Zim deal
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
